NEW YORK, July 25 - In line with a recent warning that sales of GeneChip products and do-it-yourself arraying equipment has slowed, Affymetrix reported revenues of $49.5 million for the second quarter Wednesday, compared to $45.4 million in the same period last year.  

These revenues comprised a total nine percent increase over the year-ago quarter, and landed at the high end of the company's revised revenue outlook of between $44 to $50 million. The company issued these figures in June, cutting back on initial revenue projection of between $56 and $58 million.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.